CervoMed's Upcoming Engagements at Investor Conferences
CervoMed Inc. (NASDAQ: CRVO), a pioneering clinical-stage company dedicated to developing advanced treatments for age-related neurologic disorders, has exciting news for investors. The company will be actively participating in several upcoming investor conferences during the month of November. This initiative is part of their ongoing commitment to share information about their innovative research and development progress.
Details of the Conferences
One of the notable events on their calendar is the Sidoti Virtual Micro Cap Conference. CervoMed will present a corporate overview on Thursday, November 14, 2024, at 2:30 PM ET. This presentation aims to provide insights into the company's strategic direction and the potential impact of their therapies.
Access to the Sidoti Conference
Interested parties can access the conference details and participate via webcast. The webcast link will be available for all attendees, ensuring that a broad audience can connect with CervoMed's vision and objectives. This engagement reflects CervoMed's proactive approach in keeping their stakeholders informed.
Stifel Healthcare Conference Participation
Additionally, CervoMed is scheduled for the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 3:00 PM ET. This corporate presentation is another opportunity for management to highlight CervoMed's advancements and key initiatives in the field of neurologic disorders.
CervoMed's Commitments to Neurologic Health
At the heart of CervoMed’s research is their investigational drug, neflamapimod, designed to address critical needs in treating age-related neurologic conditions. Neflamapimod is an orally administered small molecule that effectively penetrates the brain and inhibits the p38 mitogen-activated protein kinase alpha. This novel approach holds promise in managing synaptic dysfunction, a reversible factor in neurodegeneration associated with conditions like Dementia with Lewy Bodies (DLB).
Current Research and Development Status
CervoMed is currently conducting a Phase 2b study focusing on patients with early-stage DLB. The implications of their research could be transformative, offering new avenues for treatment in a landscape where options are severely limited for those suffering from these debilitating conditions.
Investor Relations and Contact Information
CervoMed encourages investors and interested stakeholders to stay updated with their progress through their official website. Information about the presentations, including webcasts and additional resources, will be prominently displayed in the Investor section, reinforcing their commitment to transparency and communication.
The Investor Contact for CervoMed is PJ Kelleher of LifeSci Advisors. He can be reached via email for any inquiries at Investors@cervomed.com, or by phone at 617-430-7579. This direct line of communication demonstrates CervoMed's readiness to engage with the investment community, ensuring all questions can be addressed promptly.
Frequently Asked Questions
What is the focus of CervoMed's research?
CervoMed specializes in developing treatments for age-related neurologic disorders, concentrating on innovative therapies like neflamapimod.
When will CervoMed present at investor conferences?
CervoMed will present at the Sidoti Virtual Micro Cap Conference on November 14, 2024, and at the Stifel 2024 Healthcare Conference on November 19, 2024.
How can investors access the conference presentations?
Investors can access the presentations via webcasts, which will be available on CervoMed's website in the Investor section.
What is neflamapimod?
Neflamapimod is an investigational drug being evaluated for its potential to treat conditions associated with neurodegeneration, specifically targeting synaptic dysfunction.
Who can I contact for more information about CervoMed?
Investors can reach out to PJ Kelleher at LifeSci Advisors by email at Investors@cervomed.com or by calling 617-430-7579.
